Keylika’s Post

Thoughts on this? >> Bluebird's $175M loan; Spyre reveals second private placement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #healthcare #biotech #pharmaceutical

The landscape of peptide therapeutics has evolved significantly over time 📈. Today, we’re leveraging the power of #generativeAI to accelerate the 4th generation of peptide drugs, creating peptides with precision and tailored drug-like properties 💊. Reach out to learn how Menten AI is forging ahead! 👋 https://www.menten.ai #hitdiscovery #drugdiscovery #drugdevelopment #peptides #peptidetherapy #cyclicpeptides #macrocycles #artificialintelligence #ai #generativeai #therapeutics #aminoacids #chemicalspace #mentenai #partnering #biotechnology #innovation

Thoughts on this? >> Bluebird's $175M loan; Spyre reveals second private placement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #biotech #pharma #healthcare

Small molecule drugs are pivotal in #drug R&D, with FDA-approved drugs targeting 812 human proteins, 84% of which are small molecules. Yet, only 639 proteins are targeted as such. Interactions between small molecule drugs and proteins primarily involve non-covalent modes, dominated currently. Challenges arise from disrupting non-covalent interactions during protein denaturation. Our platform employs photoaffinity labeling to precisely attach chemical labels to a protein's active site. Additionally, our in situ chemical crosslinking strategy converts transient non-covalent interactions into permanent covalent bonds. By utilizing a chemical probe with both photoaffinity and bioorthogonal functionalities, ChomiX's chemoproteomics platform effectively identifies #protein targets within cell lysates, tissues, and living cells. The platform's range includes bioactive small molecule drugs such as endogenous metabolites, natural products, and synthetic molecules. #DrugDevelopment #Chemoproteomics #Innovation 💊🔬🧬

Uncover the versatility of a single #cellline in dual applications — #targetedproteindegradation & compound #targetengagement. Engineered SPRINTer™ cell lines, readily used for protein turnover & #degrader potency assessments, can now be extended to measure cellular compound target engagement & rank order inhibitor studies. Read the latest #applicationnote describing this dual application that can enable acceleration of degrader discovery & development. Gain insights on characterization of #PROTACs, #molecularglues including effect of different immunomodulatory drugs (#IMiDs), & more.. https://lnkd.in/gAK6qzu7

Altimmune, a clinical-stage biotechnology company focused on developing treatments for obesity and liver disease, claimed it had a game-changer with its GLP-1 agonist, pemvidutide, which was in the trial stage to aid weight loss and manage metabolic diseases. In November 2023, Altimmune touted promising results from its 48-week Phase 2 trial for pemvidutide, setting high expectations for the drug’s potential to compete with established treatments. However, Altimmune allegedly misrepresented pemvidutide's competitive edge over other GLP-1 agonists, misleading investors about the drug’s commercial potential and the likelihood of securing strategic partnerships. In February 2024, a report by Kerrisdale Capital criticized pemvidutide’s competitiveness and efficacy, suggesting the drug was inferior to established GLP-1 treatments like Ozempic and Mounjaro, and questioned its tolerability. On this news, in February 2024, Altimmune’s stock price dropped 18.65%. In April 2024, Bloomberg reported that Guggenheim Securities downgraded Altimmune’s stock from "buy" to "neutral," citing slim chances of securing a strategic partnership for pemvidutide. On this news, Altimmune’s stock fell another 11.98%, severely damaging investors. Pomerantz was appointed Lead Counsel in an investor suit against Altimmune, alleging that the company misled investors about the potential for pemvidutide to stand out from its competitors and its prospects of finding a strategic partner to develop the treatment. #ClinicalTrials #Biotech #InvestorProtection #SecuritiesLitigation #ClassAction

Cytomos raises £5 million to expand innovative cell analysis Peter A Walker Cytomos Their technology reduces costs and accelerates drug development by six months #Investment #longevity #AgingResearch

Cytomos raises £5 million to expand innovative cell analysis Peter A Walker Cytomos Their technology reduces costs and accelerates drug development by six months

A #bacterial membrane #enzyme called histidine kinase is a great potential target for new #antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is hydrophobic. This new article demonstrates a way to make the enzyme water-soluble and available for drug research while maintaining its enzymatic function. Link to the article (open access) in the comments!

CDMOs are expected to grow by 13.8% in 2024. From my perspective, outsourcing isn't just about meetingcapacity, but tapping into real expertise and innovation, whether it's automation or scaling rapidly to meet demand. What I find most compelling is how leaders can balance internal innovation with external partnerships. Today, organizations rely on CDMOs not just for capacity but for their technical know-how and ability to handle complex challenges. This is especially true in advanced areas like cell and gene therapy. The lesson is clear for anyone leading in this space: building strong, strategic relationships with CDMOs is critical for navigating the complex and fast-paced biopharma market. #Leadership #Innovation #Biopharma #CDMO #Outsourcing #StrategicPartnerships #WittKieffer